ATE318143T1 - Gefaesszellen wachstumsfaktor (vegf) nukleinsaureligand-komplexe - Google Patents
Gefaesszellen wachstumsfaktor (vegf) nukleinsaureligand-komplexeInfo
- Publication number
- ATE318143T1 ATE318143T1 AT97912811T AT97912811T ATE318143T1 AT E318143 T1 ATE318143 T1 AT E318143T1 AT 97912811 T AT97912811 T AT 97912811T AT 97912811 T AT97912811 T AT 97912811T AT E318143 T1 ATE318143 T1 AT E318143T1
- Authority
- AT
- Austria
- Prior art keywords
- nucleic acid
- acid ligand
- vegf
- growth factor
- cell growth
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 6
- 150000007523 nucleic acids Chemical class 0.000 title abstract 6
- 102000039446 nucleic acids Human genes 0.000 title abstract 6
- 108020004707 nucleic acids Proteins 0.000 title abstract 6
- 230000010261 cell growth Effects 0.000 title 1
- 239000003102 growth factor Substances 0.000 title 1
- 210000005167 vascular cell Anatomy 0.000 title 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 5
- 150000002605 large molecules Chemical class 0.000 abstract 3
- 150000002634 lipophilic molecules Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 150000002632 lipids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/739,109 US5859228A (en) | 1995-05-04 | 1996-10-25 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| US08/870,930 US6168778B1 (en) | 1990-06-11 | 1997-06-06 | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
| US08/897,351 US6051698A (en) | 1997-06-06 | 1997-07-21 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE318143T1 true ATE318143T1 (de) | 2006-03-15 |
Family
ID=27419245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97912811T ATE318143T1 (de) | 1996-10-25 | 1997-10-17 | Gefaesszellen wachstumsfaktor (vegf) nukleinsaureligand-komplexe |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP1685842A3 (https=) |
| JP (2) | JP3626503B2 (https=) |
| KR (1) | KR100514929B1 (https=) |
| AT (1) | ATE318143T1 (https=) |
| AU (1) | AU733674B2 (https=) |
| CA (1) | CA2269072C (https=) |
| DE (3) | DE69735292T2 (https=) |
| DK (1) | DK0957929T3 (https=) |
| ES (1) | ES2259188T3 (https=) |
| FR (1) | FR06C0021I2 (https=) |
| GE (1) | GEP20094799B (https=) |
| IL (2) | IL129497A0 (https=) |
| LU (1) | LU91252I2 (https=) |
| NL (1) | NL300234I2 (https=) |
| NZ (1) | NZ334859A (https=) |
| PT (1) | PT957929E (https=) |
| RU (1) | RU2177950C2 (https=) |
| WO (1) | WO1998018480A1 (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346611B1 (en) | 1990-06-11 | 2002-02-12 | Gilead Sciences, Inc. | High affinity TGfβ nucleic acid ligands and inhibitors |
| US6232071B1 (en) * | 1990-06-11 | 2001-05-15 | Gilead Sciences, Inc. | Tenascin-C nucleic acid ligands |
| US6395888B1 (en) | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
| AU782620B2 (en) * | 1991-06-10 | 2005-08-11 | Gilead Sciences, Inc. | High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors |
| US6762290B1 (en) | 1999-07-29 | 2004-07-13 | Gilead Sciences, Inc. | High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| KR100758158B1 (ko) | 1999-07-14 | 2007-09-12 | 알자 코포레이션 | 중성 지질중합체 및 그를 함유하는 리포솜 조성물 |
| US7312325B2 (en) * | 2000-09-26 | 2007-12-25 | Duke University | RNA aptamers and methods for identifying the same |
| US7629456B2 (en) * | 2001-10-26 | 2009-12-08 | Noxxon Pharma Ag | Modified L-nucleic acid |
| WO2003039404A2 (en) * | 2001-11-09 | 2003-05-15 | Eyetech Pharmaceuticals | Methods for treating ocular neovascular diseases |
| US7094410B2 (en) * | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
| US7767803B2 (en) | 2002-06-18 | 2010-08-03 | Archemix Corp. | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics |
| WO2004012773A1 (en) * | 2002-07-24 | 2004-02-12 | F. Hoffmann-La Roche Ag | Polyalkylene glycol acid additives |
| JP2005533862A (ja) | 2002-07-25 | 2005-11-10 | アーケミックス コーポレイション | 調節されたアプタマー治療剤 |
| US9303262B2 (en) | 2002-09-17 | 2016-04-05 | Archemix Llc | Methods for identifying aptamer regulators |
| US8039443B2 (en) | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US10100316B2 (en) | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
| US20040197804A1 (en) | 2002-12-03 | 2004-10-07 | Keefe Anthony D. | Method for in vitro selection of 2'-substituted nucleic acids |
| RU2234097C1 (ru) * | 2003-03-05 | 2004-08-10 | Московский областной научно-исследовательский клинический институт | Способ диагностики саркомы капоши |
| FR2852606A1 (fr) * | 2003-03-18 | 2004-09-24 | Inst Nat Sante Rech Med | Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie |
| EP2924119A1 (en) | 2003-04-21 | 2015-09-30 | Archemix LLC | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| CL2004001996A1 (es) * | 2003-08-08 | 2005-05-06 | Eyetech Pharmaceuticals Inc | Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion. |
| PL3385384T3 (pl) | 2004-02-12 | 2021-03-08 | Archemix Llc | Aptamerowe środki terapeutyczne użyteczne w leczeniu zaburzeń powiązanych z dopełniaczem |
| US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| WO2005110489A2 (en) * | 2004-04-13 | 2005-11-24 | (Osi) Eyetech, Inc. | Nucleic acid aptamers conjugated to high molecular weight steric groups |
| US7579450B2 (en) | 2004-04-26 | 2009-08-25 | Archemix Corp. | Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics |
| US7566701B2 (en) | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
| JP2008512097A (ja) | 2004-09-07 | 2008-04-24 | アーケミックス コーポレイション | アプタマー医薬品化学 |
| EP3034089A1 (en) | 2004-11-02 | 2016-06-22 | Archemix LLC | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| KR20080025181A (ko) | 2005-06-30 | 2008-03-19 | 아케믹스 코포레이션 | 완전 2'-변형된 핵산 전사체를 생성하기 위한 물질 및 방법 |
| US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
| EP1912676A2 (en) * | 2005-07-28 | 2008-04-23 | (Osi) Eyetech, Inc. | Cyclitol linker polymer conjugate |
| ES2577514T3 (es) | 2005-08-22 | 2016-07-15 | The Regents Of The University Of California | Antagonistas de TLR |
| KR100877824B1 (ko) | 2005-11-11 | 2009-01-12 | 한국생명공학연구원 | Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도 |
| JP2009518024A (ja) * | 2005-12-06 | 2009-05-07 | ドマンティス リミテッド | Ｅｇｆｒおよび／またはｖｅｇｆに対して結合特異性を有するリガンドおよびその使用法 |
| CA2633063A1 (en) * | 2005-12-16 | 2007-06-21 | Diatos | Cell penetrating peptide conjugates for delivering of nucleic acids intocells |
| WO2007080902A1 (ja) * | 2006-01-11 | 2007-07-19 | Kyowa Hakko Kogyo Co., Ltd. | 眼球において標的遺伝子の発現を抑制する組成物および眼球における疾患の治療剤 |
| KR101584468B1 (ko) | 2006-03-08 | 2016-01-13 | 아케믹스 엘엘씨 | 안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제 |
| ES2552471T3 (es) | 2007-02-07 | 2015-11-30 | The Regents Of The University Of California | Conjugados de agonistas de TLR sintéticos y usos de los mismos |
| US20110229498A1 (en) | 2008-05-08 | 2011-09-22 | The Johns Hopkins University | Compositions and methods for modulating an immune response |
| ES2600781T3 (es) * | 2008-12-04 | 2017-02-10 | Curna, Inc. | Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf |
| PT2414322T (pt) | 2009-03-20 | 2022-12-07 | Egen Inc | Derivados de poliamina |
| US20120295811A1 (en) | 2009-11-23 | 2012-11-22 | Jean-Jacques Toulme | Aptamers directed against the matrix protein-1 of type a influenza viruses and uses thereof |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| EP2618846A1 (en) * | 2010-09-24 | 2013-07-31 | Mallinckrodt LLC | Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers |
| US20150337308A1 (en) | 2012-04-11 | 2015-11-26 | Chu De Bordeaux | Matrix metalloproteinase 9 (mmp-9) aptamer and uses thereof |
| US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
| AU2013340414B2 (en) | 2012-10-23 | 2019-05-02 | Caris Science, Inc. | Aptamers and uses thereof |
| EP2935628B1 (en) | 2012-12-19 | 2018-03-21 | Caris Life Sciences Switzerland Holdings GmbH | Compositions and methods for aptamer screening |
| WO2014148638A1 (ja) | 2013-03-22 | 2014-09-25 | 国立大学法人東京大学 | Ｉｌ－１７に対するアプタマー及びその使用 |
| AU2014286996A1 (en) | 2013-07-12 | 2016-01-07 | Iveric Bio, Inc. | Methods for treating or preventing ophthalmological conditions |
| AU2014312211A1 (en) | 2013-08-28 | 2016-03-10 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
| PT3230316T (pt) | 2014-12-11 | 2022-02-24 | Bayer Healthcare Llc | Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa |
| CA2971830A1 (en) | 2014-12-29 | 2016-07-07 | Bonac Corporation | Composition containing nucleic acid molecule stably |
| WO2016145128A1 (en) | 2015-03-09 | 2016-09-15 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
| CA2991045A1 (en) | 2015-06-29 | 2017-01-05 | Caris Science, Inc. | Therapeutic oligonucleotides binding c1q |
| AU2016298317B2 (en) | 2015-07-28 | 2021-02-18 | Caris Science, Inc. | Targeted oligonucleotides |
| WO2017046140A1 (en) | 2015-09-18 | 2017-03-23 | Bayer Pharma Aktiengesellschaft | Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia |
| EP4339288A3 (en) | 2016-03-18 | 2024-06-05 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
| US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
| CA3025486A1 (en) | 2016-05-25 | 2017-11-30 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
| EP3332812A1 (en) | 2016-12-07 | 2018-06-13 | Rheinische Friedrich-Wilhelms-Universität Bonn | Nucleic acid-based assembly and use of the assembly in cancer therapy |
| TW201904610A (zh) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | 用於治療新生血管型青光眼之非抗體vegf拮抗劑 |
| ES2999266T3 (en) | 2017-07-04 | 2025-02-25 | Daiichi Sankyo Co Ltd | Drug for retinal degenerative disease associated with photoreceptor degeneration |
| WO2019210097A1 (en) * | 2018-04-25 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Aptamers with stability, potency or half-life for enhanced safety and efficacy |
| GB202405551D0 (en) | 2024-04-19 | 2024-06-05 | Vvb Bio Pte Ltd | Combination treatment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0462145B1 (en) * | 1989-03-07 | 1994-04-27 | Genentech, Inc. | Covalent conjugates of lipid and oligonucleotide |
| US5459015A (en) * | 1990-06-11 | 1995-10-17 | Nexstar Pharmaceuticals, Inc. | High-affinity RNA ligands of basic fibroblast growth factor |
| US5811533A (en) * | 1990-06-11 | 1998-09-22 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
| US6168778B1 (en) * | 1990-06-11 | 2001-01-02 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
| US5849479A (en) * | 1990-06-11 | 1998-12-15 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
| WO1996027604A1 (en) * | 1995-03-06 | 1996-09-12 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to secretory phospholipase a2(spla2) |
| ES2336857T3 (es) * | 1995-05-04 | 2010-04-16 | Gilead Sciences, Inc. | Complejos de ligandos de acido nucleico. |
-
1997
- 1997-10-17 DE DE69735292T patent/DE69735292T2/de not_active Expired - Lifetime
- 1997-10-17 KR KR10-1999-7003488A patent/KR100514929B1/ko not_active Expired - Lifetime
- 1997-10-17 ES ES97912811T patent/ES2259188T3/es not_active Expired - Lifetime
- 1997-10-17 AT AT97912811T patent/ATE318143T1/de active
- 1997-10-17 AU AU49904/97A patent/AU733674B2/en not_active Expired
- 1997-10-17 JP JP52055398A patent/JP3626503B2/ja not_active Expired - Lifetime
- 1997-10-17 CA CA002269072A patent/CA2269072C/en not_active Expired - Lifetime
- 1997-10-17 WO PCT/US1997/018944 patent/WO1998018480A1/en not_active Ceased
- 1997-10-17 EP EP06003279A patent/EP1685842A3/en not_active Withdrawn
- 1997-10-17 GE GEAP199711120A patent/GEP20094799B/en unknown
- 1997-10-17 DE DE1997635292 patent/DE122006000029I1/de active Pending
- 1997-10-17 PT PT97912811T patent/PT957929E/pt unknown
- 1997-10-17 DK DK97912811T patent/DK0957929T3/da active
- 1997-10-17 RU RU99110377/04A patent/RU2177950C2/ru active
- 1997-10-17 IL IL12949797A patent/IL129497A0/xx unknown
- 1997-10-17 DE DE200612000029 patent/DE122006000029I2/de active Active
- 1997-10-17 EP EP97912811A patent/EP0957929B1/en not_active Expired - Lifetime
- 1997-10-17 NZ NZ334859A patent/NZ334859A/xx not_active IP Right Cessation
-
1999
- 1999-04-19 IL IL129497A patent/IL129497A/en not_active IP Right Cessation
-
2004
- 2004-10-15 JP JP2004301813A patent/JP4160038B2/ja not_active Expired - Lifetime
-
2006
- 2006-06-14 LU LU91252C patent/LU91252I2/fr unknown
- 2006-07-03 FR FR06C0021C patent/FR06C0021I2/fr active Active
- 2006-07-20 NL NL300234C patent/NL300234I2/nl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR06C0021I2 (fr) | 2007-08-03 |
| JP4160038B2 (ja) | 2008-10-01 |
| EP0957929A4 (en) | 2003-06-25 |
| AU4990497A (en) | 1998-05-22 |
| NZ334859A (en) | 2001-02-23 |
| RU2177950C2 (ru) | 2002-01-10 |
| PT957929E (pt) | 2006-06-30 |
| JP2001505191A (ja) | 2001-04-17 |
| JP3626503B2 (ja) | 2005-03-09 |
| ES2259188T3 (es) | 2006-09-16 |
| EP1685842A3 (en) | 2006-11-29 |
| DE69735292T2 (de) | 2006-10-19 |
| EP0957929B1 (en) | 2006-02-22 |
| AU733674B2 (en) | 2001-05-24 |
| CA2269072C (en) | 2006-02-14 |
| LU91252I2 (fr) | 2006-08-14 |
| DE122006000029I1 (de) | 2006-10-19 |
| CA2269072A1 (en) | 1998-05-07 |
| NL300234I2 (nl) | 2006-10-02 |
| IL129497A0 (en) | 2000-02-29 |
| JP2005046160A (ja) | 2005-02-24 |
| DE122006000029I2 (de) | 2007-11-08 |
| KR100514929B1 (ko) | 2005-09-15 |
| IL129497A (en) | 2009-06-15 |
| EP0957929A1 (en) | 1999-11-24 |
| WO1998018480A1 (en) | 1998-05-07 |
| NL300234I1 (nl) | 2006-09-01 |
| GEP20094799B (en) | 2009-10-26 |
| KR20000052697A (ko) | 2000-08-25 |
| DE69735292D1 (de) | 2006-04-27 |
| DK0957929T3 (da) | 2006-07-03 |
| EP1685842A2 (en) | 2006-08-02 |
| FR06C0021I1 (https=) | 2006-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE318143T1 (de) | Gefaesszellen wachstumsfaktor (vegf) nukleinsaureligand-komplexe | |
| DE69638099D1 (de) | Nukleinsäureligand-komplexe | |
| CY1114352T1 (el) | Συμπλοκα συνδετηρων νουκλεϊνικου οξεος παραγοντα αναπτυξης που λαμβανεται απο αιμοπεταλιο (pdgf) | |
| ATE277058T1 (de) | Polyazomacrocyclofluoromonoalkylphosphensäure, ihre komplexe zur verwendung als kontrastmittel | |
| DE59000326D1 (de) | Verfahren zur herstellung von 3-amino-5-aminocarbonyl-1,2,4-triazol-derivaten. | |
| DE69834649D1 (de) | Tie ligand-homologuen | |
| DE69109131D1 (de) | Verfahren zur herstellung von molekularsieben, einschliesslich zeolithen, mit metallchelat-komplexen. | |
| DE58903401D1 (de) | Cyclohexenonoximether, verfahren zu ihrer herstellung und ihre verwendung als herbizid. | |
| NO885836D0 (no) | Kvantitativ metode for bestemmelse av 1,4-dihydronikotinamid-adenin-dinukleotid i opploesning. | |
| IT8821185A0 (it) | Turbopompa molecolare. | |
| ATE428500T1 (de) | Kunststoff-geträgerte phosphorliganden verwendbar in der katalyse | |
| DE58900514D1 (de) | Verfahren zur herstellung von 1,2,4-butantriol. | |
| DE59002382D1 (de) | Alkadiennitrile, verfahren zu ihrer herstellung und ihre verwendung. | |
| DE3582702D1 (de) | Neue metallkomplexe, verfahren zu ihrer herstellung ihre verwendung zum faerben von hochmolekularem organischem material. | |
| DE3875512D1 (de) | Dufterzeugnis mit gesteuerter abgabe und verfahren zu seiner herstellung. | |
| DE58909268D1 (de) | Wasserlösliche Farbstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung. | |
| DE3862331D1 (de) | Wasserloesliche azoverbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbstoffe. | |
| DE3765504D1 (de) | Wasserloesliche triphendioxazin-verbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbstoffe. | |
| DeTreville | SENATUS ET RELIGIO: ASPECTS OF THE ROMAN SENATE'S ROLE IN THE STATE RELIGION DURING THE REPUBLIC. | |
| DE3872648D1 (de) | Alkanoylesterverbindungen, zwischenverbindungen dazu und verfahren zur herstellung. | |
| DE3765050D1 (de) | Wasserloesliche triphendioxazin-verbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbstoffe. | |
| DE58903335D1 (de) | Neue aromatische polyethersulfone, verfahren zu ihrer herstellung und ihre verwendung. | |
| ATE261436T1 (de) | Verfahren zu herstellung von substituierten pyranen | |
| ATE89284T1 (de) | Aminoanthracendion-bis-platinkomplexe, nuetzlich als antitumor-agenzien. | |
| DE59102844D1 (de) | Wasserlösliche faserreaktive farbstoffe, verfahren zu ihrer herstellung und ihre verwendung. |